# Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease

> **NCT02539368** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 2565 (actual)

## Conditions studied

- Inflammatory Bowel Diseases
- Ulcerative Colitis
- Crohn's Disease

## Interventions

- **DRUG:** CT-P13
- **DRUG:** Remicade

## Key facts

- **NCT ID:** NCT02539368
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-22
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-10-31
- **Target enrollment:** 2565 (ACTUAL)
- **Last updated:** 2020-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02539368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02539368, "Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02539368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*